Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and ...

Dr Reddy's Laboratories and Alvotech join forces to co-develop and commercialize a biosimilar to Keytruda (pembrolizumab) for ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (Alvotech), and Dr. Reddy's Laboratories announced that ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

A grandad diagnosed with stage 4 lung cancer–one of the deadliest—has become disease-free after being treated with an ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...